Search results for "vaccine."

showing 10 items of 789 documents

COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Ita…

2021

The coronavirus disease 2019 (COVID-19) pandemic has not finished yet, and the most promising option towards its ending is widespread vaccination. Because patients with inflammatory bowel diseases (IBDs), namely Crohn’s disease (CD) and ulcerative colitis (UC), often require immune-modifying treatment, which might increase the risk of opportunistic infection,1 their vaccination history for several infectious diseases is routinely checked, and when inadequate, vaccination is performed at diagnosis or ideally before immune suppressive treatment is started.1 However, IBD patients were not found to be at an increased risk of developing COVID-19 or of experiencing a more severe disease course.2

medicine.medical_specialty2019-20 coronavirus outbreakCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)IBDBrief Report - ClinicalInternal medicinemedicineHumansImmunology and AllergyIn patientAcademicSubjects/MED00260SARS-CoV-2business.industryVaccinationGastroenterologyCOVID-19Inflammatory Bowel DiseasesInflammatory Bowel DiseasesCOVID-19 Vaccines HumanVaccinationIBD Crohn Ulcerative Colitis Vaccination Covid 19 Sars-Cov 2COVID-19; COVID-19 vaccine; IBD; vaccine hesitancyvaccine hesitancybusinessCOVID-19 vaccineInflammatory Bowel Diseases
researchProduct

El Instituto Médico Valenciano y la difusión de la vacuna

2004

The Medical Valencian Institute promoted a campaign of smallpox free vaccination (1851- 1894) by means of humanized vaccine sent from England. It spread the vaccination for the whole Spain and published careful statistics of the vaccinations practised in the Bulletin of the Medical Valencian Institute. The National Institute of Vaccination (1871) did not recognize his labor and one denied to him the category of Provincial Institute of Vaccination.

medicine.medical_specialty:CIENCIAS DE LA VIDA::Inmunología ::Vacunas [UNESCO]lcsh:R131-687Valencianinstituto médico valencianoInstituto Nacional de VacunaciónHistory and Philosophy of Sciencelcsh:History of medicine. Medical expeditionsAZ20-999lcsh:AZ20-999medicineSmallpoxinstitut mèdic valenciàmedical valencian institute:HISTORIA::Historia por especialidades::Historia de la medicina [UNESCO]vaccination statisticsHistory of medicine. Medical expeditionsR131-687smallpox vaccineUNESCO::CIENCIAS DE LA VIDA::Inmunología ::Vacunasbusiness.industryestadístiques de vacunaciómedicine.disease:CIENCIAS MÉDICAS [UNESCO]lcsh:History of scholarship and learning. The humanitieslanguage.human_languageVaccinationFamily medicineUNESCO::HISTORIA::Historia por especialidades::Historia de la medicinaUNESCO::CIENCIAS MÉDICASlanguageHistory of scholarship and learning. The humanitiespigotavacuna antivariólicabusinessNational Institute of Vaccinationestadísticas de vacunaciónDemography
researchProduct

Assessing vaccine efficacy for the prevention of acute otitis media by pneumococcal vaccination in children: a methodological overview of statistical…

2006

Acute otitis media (AOM) is the most common bacterial infectious disease among children. Vaccination is proposed to prevent otitis and several clinical trials were performed to assess the efficacy of pneumococcal vaccines. The way vaccine efficacy is analysed varies among trials. However, the clinical meaning of an estimate of vaccine effect and its statistical test depends on the applied statistical method. We aim to bring the meaning and validity of statistical trial results to the attention of researchers. We consider all methodological approaches for analysing vaccine efficacy applied in pneumococcal vaccination trials included in a recent Cochrane Review. We demonstrate how different m…

medicine.medical_specialtyAcute otitis mediaPneumococcal InfectionsPneumococcal VaccinesmedicineHumansIntensive care medicineChildRandomized Controlled Trials as TopicGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryMiddle ear diseasePublic Health Environmental and Occupational HealthInfantVaccine efficacyClinical trialVaccinationOtitis MediaInfectious DiseasesOtitisInfectious disease (medical specialty)Research DesignChild PreschoolPneumococcal vaccinationImmunologyMolecular Medicinemedicine.symptombusinessVaccine
researchProduct

The seroepidemiology of pertussis in Australia during an epidemic period

2006

Studying the epidemiology of pertussis and impact of differing vaccine schedules is difficult because of differing methods of case ascertainment. The advent of internationally standardized serological diagnosis for recent infection has allowed comparison of age-specific pertussis infection among European countries and was applied in Australia at the time of a major national epidemic. In 1997 and 1998, a nationally representative serum bank using residual sera from diagnostic laboratories was established. Measurement of pertussis toxin (PT) IgG level was conducted by a reference laboratory using an enzyme-linked immunosorbent assay standardized for a number of European countries. A titre of …

medicine.medical_specialtyAdolescentWhooping CoughEpidemiologyVaccination scheduleReference laboratoryPertussis toxinBordetella pertussisSerologySeroepidemiologic StudiesEpidemiologymedicineHumansChildAustralia/epidemiology Diphtheria-Tetanus-Pertussis Vaccine/administration & dosage AdolescentDiphtheria-Tetanus-Pertussis VaccineWhooping coughTransmission (medicine)business.industryAustraliaInfantmedicine.diseaseVaccinationInfectious DiseasesChild PreschoolPopulation SurveillanceImmunologybusinessResearch ArticleDemographyEpidemiology and Infection
researchProduct

Cutaneous and Allergic reactions due to COVID‐19 vaccinations: A review

2021

ABSTRACT Introduction The pandemic caused by the novel coronavirus disease 2019 (COVID‐19) has had an unprecedented impact on the overall health and the global economy. Vaccination is currently the most dependable strategy to end the pandemic, despite the slower‐than‐hoped‐for rollout, particularly for low‐to‐middle‐income countries, and the uncertain duration of protection afforded by vaccination. The spike protein of the virus (immunodominant antigen of the virus) is the main target of the approved and candidate SARS‐CoV‐2 vaccines. This protein binds to the ACE2 receptor of the host cell, initiating the entry of the virus into the cell and the chain of subsequent events ending to Acute R…

medicine.medical_specialtyAllergyCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)ExacerbationReview ArticleDermatologyallergic reactionsmedicine.disease_causeSARS‐CoV‐2VirusAntigenCOVID‐19PandemicHypersensitivityHumansMedicineIntensive care medicineReview ArticlesCoronavirusbusiness.industryVaccinationCOVID-19cutaneous reactionsmedicine.diseaseVaccinationBNT162b2mRNA VaccinesbusinessJournal of Cosmetic Dermatology
researchProduct

Allergy to Polyethilenglicole of Anti-SARS CoV2 Vaccine Recipient: A Case Report of Young Adult Recipient and the Management of Future Exposure to SA…

2021

The main contraindication to the anti-SARS CoV2 vaccine is an anaphylactic reaction to a vaccine component. The need to vaccinate allergic people who are at higher risk can be of public health interest and this report shows a case of an allergic reaction to PEG of a HCW who had received the first dose of anti-SARS CoV2 vaccine. For 5 h after the administration of the vaccine, she had the appearance of erythematous spots on the face and neck, and a feeling of a slurred mouth and hoarseness. In order to treat the event, she was administered 8 mg intravenous dexamethasone, 1 vial intravenous chlorphenamine maleate, 250 mL intravenous 0.9% NaCl, and conventional oxygen therapy (2 L/min) with co…

medicine.medical_specialtyAllergyImmunologyadverse reactionCase ReportVial03 medical and health sciences0302 clinical medicineInternal medicinevaccineDrug DiscoverymedicineanaphylaxisPharmacology (medical)030212 general & internal medicineAdverse effectContraindicationDexamethasonePharmacologym-RNA vaccinebusiness.industrySARS CoV2Rmedicine.diseasePEGAdverse reaction Anaphylaxis Basophil activation test Contraindica-tion M-RNA vaccine PEG SARS CoV2 VaccineVaccinationInfectious Diseases030228 respiratory systembasophil activation testMedicinebusinessAnaphylaxisAdverse drug reactioncontraindicationmedicine.drugVaccines
researchProduct

Are licensed canine parvovirus (CPV2 and CPV2b) vaccines able to elicit protection against CPV2c subtype in puppies?: A systematic review of controll…

2015

Severe gastroenteritis caused by canine parvovirus type 2 (CPV2) is a serious life-threatening disease in puppies less than 4-months of age. The emergence of new variants has provoked some concern about the cross-protection elicited by licensed canine parvovirus modified-live type 2 (CPV2) and type 2b (CPV2b) vaccines against the most recent subtype CPV2c. A systematic review was carried out to assess the efficacy of commercial vaccines. We conducted a literature search of Pub Med/MEDLINE from January 1990 to May 2014. This was supplemented by hand-searching of related citations and searches in Google/Google Scholar. Controlled clinical trials in which vaccinated puppies were challenged wit…

medicine.medical_specialtyBlindingParvovirus CanineCross ProtectionDiseaseMicrobiologyParvoviridae InfectionsDogsSpecies SpecificityInternal medicineAnimalsMedicineDog DiseasesViral sheddingGeneral Veterinarybiologybusiness.industryViral VaccineCanine parvovirusViral VaccinesGeneral Medicinebiology.organism_classificationVaccine efficacyGastroenteritisVirus SheddingClinical trialSystematic reviewImmunologybusinessVeterinary Microbiology
researchProduct

Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives

2022

La pandemia por COVID-19 ha supuesto un reto para los países y sus profesionales sanitarios. La entrada viral en el hospedador a través del receptor ACE-2 y una activación excesiva del sistema inmunológico son claves para comprender tanto la incidencia como la gravedad de la enfermedad. La enfermedad inflamatoria intestinal (EII) representa una condición especial asociada con una respuesta descontrolada del sistema inmunológico a agentes externos. Los tratamientos para la EII se han asociado con un mayor riesgo de infecciones bacterianas y virales. Esto ha planteado la cuestión de una posible mayor incidencia y gravedad de la infección por COVID-19 en pacientes con EII. A lo largo de este a…

medicine.medical_specialtyCOVID-19 VaccinesIBD-treatmentCOVID-19 VaccinePopulationDiseaseIncidencia por COVID-19COVID-19 graveInflammatory bowel diseaseSulfasalazineInternal medicinetratamiento de la EIIPandemicmedicineHumansEnfermedad Inflamatoria Intestina (EII)Inflammatory Bowel Disease (IBD)educationSevere COVID-19Pandemicseducation.field_of_studyTofacitinibHepatologybusiness.industryVacuna COVID-19Incidence (epidemiology)GastroenterologyRevisadoCOVID-19General Medicinemedicine.diseaseInflammatory Bowel DiseasesVaccinationCOVID-19 incidenceTumor Necrosis Factor Inhibitorsbusinessmedicine.drugGastroenterología y Hepatología (English Edition)
researchProduct

An Insight into the Role of Postmortem Immunohistochemistry in the Comprehension of the Inflammatory Pathophysiology of COVID-19 Disease and Vaccine-…

2021

On 11 March 2020, the World Health Organization (WHO) declared a pandemic due to the spread of COVID-19 from Wuhan, China, causing high mortality rates all over the world. The related disease, which mainly affects the lungs, is responsible for the onset of Diffuse Alveolar Damage (DAD) and a hypercoagulability state, frequently leading to Severe Acute Respiratory Syndrome (SARS) and multiorgan failure, particularly in old and severe-critically ill patients. In order to find effective therapeutic strategies, many efforts have been made aiming to shed light on the pathophysiology of COVID-19 disease. Moreover, following the late advent of vaccination campaigns, the need for the comprehension …

medicine.medical_specialtyCOVID-19 VaccinesQH301-705.5AutopsyReviewDiseaseCatalysisInorganic ChemistryvaccinePandemicHumansMedicineEndotheliumBiology (General)Physical and Theoretical ChemistryIntensive care medicineDiffuse alveolar damageAdverse effectQD1-999Molecular BiologypathophysiologySpectroscopypostmortemChAdOx1 nCov-19SARS-CoV-2business.industryMechanism (biology)Organic ChemistryCOVID-19ThrombosisGeneral MedicinePathophysiologyComputer Science ApplicationsVaccinationChemistryimmunohistochemistryCytokinesAutopsybusinessInternational Journal of Molecular Sciences
researchProduct

Italian association for the study of the liver position statement on SARS-CoV2 vaccination.

2021

The vaccination campaign against Sars-CoV-2 commenced in Italy at the end of December 2020. The first ones to receive the immunization against the virus were the health workers and the residents of nursing homes, following which the vaccine would be available for the entire population, beginning with the most vulnerable individuals. SARS-CoV2 vaccines have been demonstrated to be safe for the general population, although no data for patients with liver diseases or those having undergone liver transplantation are available so far. The present position statement AISF is an attempt to suggest, based on the published data on the impact of Sars-Cov-2 infection in patients with chronic liver dise…

medicine.medical_specialtyCOVID-19 VaccinesSars-CoV-2medicine.medical_treatmentPopulationLiver transplantationChronic liver diseaseRisk AssessmentPatient safetyEpidemiologyMedicineChronic liver disease Sars-CoV-2 Vaccination Humans Immunosuppressive Agents Italy Liver Transplantation Patient Safety Patient Selection Risk Adjustment Risk Assessment SARS-CoV-2 Transplant Recipients Treatment Outcome COVID-19 COVID-19 Vaccines Immunization Programs Liver DiseasesHumanseducationeducation.field_of_studyHepatologybusiness.industryImmunization ProgramsLiver DiseasesPatient SelectionChronic liver disease; Sars-CoV-2; VaccinationVaccinationChronic liver diseaseGastroenterologyCOVID-19medicine.diseaseTransplant RecipientsLiver TransplantationVaccinationTreatment OutcomeImmunizationItalyFamily medicineChronic liver disease; Sars-CoV-2; Vaccination; Humans; Immunosuppressive Agents; Italy; Liver Transplantation; Patient Safety; Patient Selection; Risk Adjustment; Risk Assessment; SARS-CoV-2; Transplant Recipients; Treatment Outcome; COVID-19; COVID-19 Vaccines; Immunization Programs; Liver DiseasesRisk AdjustmentPatient SafetyPosition PaperbusinessRisk assessmentImmunosuppressive AgentsDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct